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1 Shao-Yang Hu and Chen-Chen Tai contributed equIt is well known that growth hormone (GH)-induced IGF-1 signaling plays a dominant role in post-
natal muscle growth. Our previous studies have identiﬁed a growth factor, progranulin (PGRN), that
is co-induced with IGF-1 upon GH administration. This result prompted us to explore the function of
PGRN and its association with IGF-1. In the present study, we demonstrated that, similar to IGF-1,
PGRN can promote C2C12 myotube hypertrophy via the PI(3)K/Akt/mTOR pathway. Moreover, PGRN
can rescue the muscle atrophy phenotypes in C2C12 myotube when IGF-1 signaling is blocked. This
result shows that PGRN can substitute for IGF-1 signaling in the regulation of muscle growth. Our
ﬁndings provide new insights into IGF-1-modulated complicated networks that regulate muscle
growth.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The growth hormone (GH)/insulin-like growth factor-1 (IGF-1)
axis plays an important role in the regulation of muscle growth
[1]. GH-mediated growth has been postulated to be stimulated
by GH-induced hepatic IGF-I secretion (endocrine mode) and local
IGF-1 production (autocrine and/or paracrine mode) [2]. However,
a comparative analysis has shown that GH receptors (GHR) and
IGF-1 double mutant mice exhibit a more severe growth defect
than single mutant mice. This ﬁnding suggests that the effects of
GH on muscles may not depend exclusively on IGF-1 [3]. To inves-
tigate other growth factors involved in muscle growth, down-
stream effectors of GH signaling have been studied extensively.
We previously have shown that the epithelial tissue growth factor
progranulin (PGRN) is induced along with IGF-1 by GH administra-
tion. This result suggests that PGRN participates in GH/IGF-1 axis-
regulated growth and may serve functions similar to those of IGF-1
signaling [4]. IGF-1 is a critical regulator of skeletal muscle devel-
opment. It participates in many stages of muscle growth from the
proliferation and differentiation of myoblasts to myotube hyper-
trophy [5,6]. The binding of IGF-1 to IGF-1 receptors (IGF-1R) notchemical Societies. Published by E
arine Molecular Biology and
ic Biology, Academia Sinica,
15, Taiwan.
.
ally to this work.only causes muscle hypertrophy through activations of phosphati-
dyl inositol-3 kinase (PI3K)/Akt and its downstream targets mTOR,
p70S6K, and PHAS-1/4E-BP1[7], but it also leads to the mitogenesis
of muscle cells via the mitogen-activated protein kinase (MAPK)
pathway [5]. PGRN and IGF-1 act on similar downstream signaling
pathways; for instance, the MAPK and PI3K/Akt pathways are both
involved in PGRN-mediated cell migration and growth [8,9]. In
addition, PGRN is connected to IGF-1 in various manners. PGRN-
induced proliferation effects are observed in IGF-1 receptor null
3T3 cells via activation of the MAPK and PI3K/Akt/p70S6K pathways
[10,11]. Although the regulatory roles of IGF-1 signaling in muscle
development are well known, the function and regulatory roles of
PGRN remain unclear.
PGRN is a secreted growth factor that has been implicated in a
wide variety of biological processes, including wound healing,
embryo development, morphogenesis, and cancer diseases [12].
Genetic analysis has recently shown that mutation within the
PGRN gene is a major cause of frontotemporal lober degeneration
(FTLD), which is one of the most common form of neurodegenera-
tive disease accounting for 510% of all patients diagnosed with
dementia [13–15]. This result suggests that PGRN is an emerging
target for FTLD therapies. Furthermore, gene expression analysis
elucidated that PGRN is upregulated in various neuroinﬂammatory
conditions, and increased PGRN expression by microglia poten-
tially plays a pivotal role in responses to neuroinﬂammation,
neurodegeneration, and brain injury [16]. Regarding zebraﬁsh,
knockdown of the PGRN gene using antisense morpholinos leadlsevier B.V. All rights reserved.
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cating PGRN plays a vital role in embryonic liver morphogenesis
[17]. In addition, PGRN promotes PC12 cells, which is a pheochro-
mocytoma-derived neuronal cell line lacking responses to most
nerve growth factors. IGF-1, which is similar to PGRN, is a growth
factor capable of effecting on PC12 cells [18]. In embryonic ﬁbro-
blasts, PGRN mediated similar signaling pathways similar to those
mediated by IGF-1 [19]. Although these results suggest that PGRN
possesses a role similar to IGF-1, potential importance and subtle
differences would exist between PGRN and IGF-1. The main objec-
tive of this study is to clarify the function and roles of PGRN in
muscle growth and its association with IGF-1 signaling. We dem-
onstrated that PGRN stimulates mouse C2C12 myotube hypertro-
phy and also proved that PGRN-induced myotube hypertrophy is
performed via the PI3K/Akt/mTOR signaling pathway. Further-
more, we blocked IGF-1 signaling with an IGF-1-speciﬁc inhibitor
and found that PGRN could compensate partially for the loss of
IGF-1 signaling in muscle hypertrophy. Taken together our ﬁndings
demonstrate the function of PGRN in muscle growth and indicated
a partially compensative role of PGRN for failed IGF-1 signaling.
2. Materials and methods
2.1. Cells and culture medium
C2C12 cells were maintained in Dulbecco’s modiﬁed minimum
essential medium (DMEM) supplemented with 10% fetal bovine
serum (Gibco, Grand Island, NY), 3.7 g/L sodium bicarbonate (Sig-
ma-Aldrich, St. Louis, MO, USA), and antibiotics (100 U/ml penicil-
lin and 100 lg/ml streptomycin) (Gibco) at 37 C in air with a
humidiﬁed atmosphere of 5% CO2. The myoblasts were fused into
myotubes at 50% conﬂuence by shifting the growth medium to a
differentiation medium consisting of DMEM supplemented with
2% horse serum. C2C12 cells were incubated in a differentiation
medium for 4 days to complete myotube formation. The differenti-
ation medium was renewed every 2 days. The time at which the
differentiation medium was ﬁrst introduced was referred to as
day 0. All chemical treatments, including recombinant human GH
(hGH) (GenWay, CA., USA), R3-IGF-1 (Sigma, St. Louis, MO, USA),
recombinant mouse PGRN (R& D Systems, Minneapolis, MN),
recombinant human granulin C (Adipogen, CA, USA) and human
granulin E (Abnova, CA, USA) were administered either on day 2
or day 4 after fusion as described. PQ401 (Sigma Aldrich),
LY294002 (Sigma-Aldrich) and rapamycin (Calbiochem, San Diego,
CA) were dissolved in DMSO (Sigma-Aldrich); an equal amount of
DMSO was administered as a negative control.
2.2. Quantitative PCR
RNA was extracted from C2C12 cells using RNA-Bee™ (Tel-Test,
Friendwood, TX, USA) according to the manufacturer’s instructions.
RNA sampleswere reverse transcribed using the SuperScript™ﬁrst-
strand synthesis system (Invitrogen, Carlsbad, CA). The cDNAs cor-
responding to various genes were ampliﬁed using the Fast SYBR
GreenMaster Mix (Applied Biosystems, Foster City, CA) and quanti-
ﬁed using a Roche LightCycler 480 II (Roche, Mannheim, Germany).
The reaction conditionswere 95 C for 10 min, followed by 45 cycles
of 95 C for 15 s and 60 C for 1 min. All samples were analyzed at
least in triplicate. The following mouse primers were used: PGRN
sense 5’-GTGGCTGGCCTGGAGAAGAT-3’ and antisense 5’-CCTCA
CAGCACACAGCATGG-3’; IGF-1 sense 5’-CTCAGAGCATA CCTGCCT
GG-3’ and antisense 5’-GGTACTATGAGGCCGAGGTG-3’; GAPDH
sense 5’-TCCACTCACGGCAAATTCAACG-3’ and antisense 5’-TAGA
CTCCACG ACATACTCAGC-3’. The expression of each transcript was
measured using the threshold cycle (Ct) method; GAPDH transcrip-
tion was used as an internal control. The ampliﬁcation of speciﬁctranscripts was further conﬁrmed by melting curve proﬁle analysis
and agarose gel electrophoresis.
2.3. Western blot analysis
Cells were washed brieﬂy with PBS and collected in a Mamma-
lian Cell-PE LB buffer (Geno Technology Inc., St. Louis, MO). Cell
debris was removed by centrifugation at 12000g for 10 min,
and the supernatants were used for immunoblotting analysis.
The Bradford assay (Bio-Rad, Hercules, CA) was used to measure
protein concentration. Aliquots of 50 lg protein were subjected
to 12% SDS-PAGE, and the proteins were transferred onto a PVDF
membrane (Millipore, Billerica, MA) at 25 V for 45 min in a buffer
containing 192 mM glycine and 25 mM Tris-HCl. Membranes were
blocked with 0.25% gelatin and 0.05% Tween-20 in Tris-buffered
saline for 2 h at room temperature. The membranes were then
probed with a 1:2000 dilution of the indicated antibody for 2 h
at room temperature. The used antibodies were anti-mouse PGRN
(R& D Systems), anti-Akt, anti-phospho-Akt (Ser473), anti-phospho-
GSK-3a/b (Ser21/9), anti-phospho-p70S6K (Thr389) (cell signaling
Technologies, Beverly, MA), and anti-a-tubulin (Abcam, Cam-
bridge, MA). After washing, membranes were incubated with
horseradish peroxidase-linked anti-rabbit, anti-mouse, or anti-rat
secondary antibodies for 2 h. Membranes were then incubated
with a chemiluminescence reagent (Immobilon Western, Millipore)
with gentle agitation and exposed to Hyperﬁlm ECL (GE Health-
care, Buckinghamshire, UK). Films were scanned and speciﬁc bands
were quantiﬁed using ImageQuant software (Molecular Dynamics,
Sunnyvale, CA, USA). The band intensity was normalized to the
a-tubulin band in the same sample.
2.4. WST cell proliferation
Assay C2C12 cells proliferation in response to IGF-1 and PGRN
treatments was measured using a BioVision cell proliferation kit
(Mountain View, CA) according to the manufacturers’ instructions.
Cells were ﬁrst seeded into 96-well plates, and IGF-1 or PGRN was
administered on either day 2 or day 4 after fusion as described. Fol-
lowing the treatments, 10 ll of WST reagent was added to each
well, and cells were incubated for 1 h at 37 C. Absorbance at 480
nm was measured using a Spectra Max M5 microplate reader
(Molecular Devices, Sunnyvale, CA).
2.5. Immunocytochemistry and quantitative analyses of myotubes
C2C12 cells were seeded on a sterile glass coverslip in a 6-
well plate, and the cells were ﬁxed and permeabilized with cold
acetone for 10 min. The slides were then washed 3 times with
PBS and blocked with 5% BSA in 0.1% PBST for 1 h at room tem-
perature. Cells were stained with 1:100 anti-myosin heavy chain
(MHC) antibody (R& D Systems) for 1 h. After rinsing with PBS,
cells were incubated with 1:2000 Alexa Fluor 488-conjugated
goat anti-mouse IgG secondary antibody (Invitrogen) for 1 h
and counterstained with 1.5 lg/ml DAPI (Invitrogen) for nuclei
visualization. The slides were then viewed and photographed
with an inverted ﬂuorescence microscope and a CCD camera
using MetaMorph image analysis software (Molecular Devices,
Downingtown, PA). The fusion index was deﬁned as the ratio of
nuclei within the myotubes (>2 nuclei) to the total number of
nuclei. One-thousand nuclei per culture were counted in 3 inde-
pendent cultures. The average number of nuclei per myotube was
determined by counting over 500 nuclei from randomly chosen
MHC-positive cells, and the average diameter per myotube was
calculated as the mean of 5 measurements taken along the entire
tube. At least 50 myotubes per well were measured in 3 indepen-
dent experiments.
Fig. 1. IGF-1 decreased PGRN expression in C2C12 cells through the IGF-1 receptor. PGRN or IGF-1 mRNA expression levels were determined by real-time quantitative PCR.
Myotubes were treated with (A) 100 ng/ml hGH ; (B) 20 ng/ml IGF-1; (C)20 ng/ml or 100 ng/ml IGF-1; (D) 200 ng/ml, 500 ng/ml, or 1000 ng/ml mouse PGRN; (E) PGRN
protein expression levels were analyzed by Western blotting. Myotubes were treated with 20 ng/ml IGF-1 with or without 30 lM PQ401 at day 4 for 24 h. Relative protein
levels were quantiﬁed using ImageQuant software. Data are shown in comparison with untreated cells. Data are expressed as means ± S.E. (n = 3). Star symbol indicats
signiﬁcant differences. ⁄ indicates p < 0.05; ⁄⁄ indicates p < 0.01.
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Data are expressed as mean ± S.E. Between-groups results were
compared using the Student’s t test. Statistical signiﬁcance amongmultiple experimental treatments was determined by one-way
analysis of variance (ANOVA). Tukey’s test was used to evaluate
differences among means (SAS Institute, Cary, North Carolina,
USA). Statistical signiﬁcance was determined with P values <0.05.
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3.1. IGF-1 regulates PGRN expression in C2C12 cells through the IGF-1
receptor
In our previous study, we showed that PGRN is induced along
with IGF-1 in liver tissue after GH administration. To clarify
whether GH also induced PGRN in muscle cells, differentiated
C2C12 cells were treated with recombinant hGH to estimate PGRN
and IGF-1 mRNA expression levels. The ﬁnding showed that, simi-
larly to the results in the liver, GH also induces PGRN expression
in muscle cells (Fig. 1A). To further elucidate the relationship
between PGRN and IGF-1, differentiated C2C12 cells were treated
with IGF-1 and PGRN separately. We found PGRN mRNA expres-
sion was decreased signiﬁcantly at 12 h and 24 h after treatment
with either 20 ng/ml or 100 ng/ml IGF-1 (Fig. 1B and 1C). In con-
trast, PGRN treatments did not affect IGF-1 mRNA expression, even
at concentrations of 200 ng/ml to 1000 ng/ml (Fig. 1D). These re-
sults suggest that the IGF-1 is an upstream modulator of PGRN.
To further explore whether IGF-1 regulates PGRN expression
through the IGF-1 receptor (IGF-1R), IGF-1 signaling was blocked
using the speciﬁc IGF-1R inhibitor PQ401. PQ401 has been reported
to inhibit IGF-1R autophosphorylation effectively, thus suppressingFig. 2. Effects of IGF-1 and PGRN on C2C12 myotube proliferation. Myotube
formation was indicated as described in the Materials and Methods section. Cell
proliferation was determined by WST assay. C2C12 cells were treated with (A)
100 ng/ml IGF-1; (B) 500 ng/ml or 1000 ng/ml IGF-1 at day 2 or day 4 for 24 h. Data
are expressed as means ± S.E. (n = 8). Star symbol indicates signiﬁcant differences. ⁄
indicates p < 0.05; ⁄⁄ indicates p < 0.01.IGF-1-stimulated cell growth [20]. In contrast to IGF-1 administra-
tion alone, the simultaneous addition of PQ401 and IGF-1 miti-
gated the IGF-1-mediated suppression of PGRN expression from
48 ± 2.1% to 15 ± 5%. When PQ401 only was administrated to block
endogenous IGF-1 signaling, protein expression of PGRN was ele-
vated signiﬁcantly. The amount of granulin (GRN) proteins cleaved
from PGRN did not change suggesting the variation of PGRN is due
to expression not processing (Fig. 1E). These results indicate that
PGRN suppression occurs downstream of IGF-1 signaling and that
IGF-1 regulates PGRN expression through IGF-1R.
3.2. PGRN stimulates C2C12 myotube hypertrophy
IGF-1 is known to promote proliferation and myotube hypertro-
phy in C2C12myoblasts; however, PGRN effects on myoblasts have
been unclear. To examine the functional properties of PGRN on
myoblast proliferation, PGRN was administrated on day 2 after
fusion. As found previously, myoblast proliferation was stimulated
signiﬁcantly in the presence of 100 ng/ml IGF-1 (Fig. 2A). However,
the effects of PGRN on myoblast proliferation were slight, even at
concentrations of 500 ng/ml and 1000 ng/ml (Fig. 2B). These re-
sults suggest that the critical role of PGRN in myoblast function
may not be related to its proliferation. Therefore, we further eval-
uated the effects of PGRN on C2C12 myotube hypertrophy. Several
criteria, including the measurements of the mean number of nuclei
per myotube, myotube fusion index, and myotube diameter, were
used to evaluate the state of muscle hypertrophy in response to
PGRN treatment. Immunochemistry using an anti-myosin heavy
chain (MHC) antibody showed that PGRN and IGF-1 both caused
hypertrophic phenotypes (Fig. 3A). The myotube diameters, the
fusion index and the mean number of nuclei per myotube also
increased, corresponding with the hypertrophic effects of IGF-1
and PGRN treatment (Fig. 3B, C, and D). These results show that
PGRN is able to induce myotube hypertrophy in a similar manner
to IGF-1. To further understand whether PGRN mediated myotube
hypertrophy is due to GRN fragments or not, commercially avail-
able GRN C and E were used to estimate the myotube hypertrophy
effect. According to the criteria of phenotype, fusion index and the
mean number of nuclei per myotube, GRN C and E did not affect
myotube htpetrophy (Supplementary Fig. S1). These results sug-
gest that the PGRN mediated myotube hypertrophy potentially
through PGRN alone.
3.3. PGRN induced myotube hypertrophy by the PI(3)K/Akt/mTOR
pathway
To determine whether PGRN-induced myotube hypertrophy is
mediated through the PI(3)K/Akt/mTOR pathway as is IGF-1, the
effects of pharmacological inhibitors of the PI(3)K/Akt/mTOR sig-
naling pathway on myotube hypertrophy were evaluated. Treat-
ment with 20 lM LY294002, which is a speciﬁc inhibitor of
PI(3)K/Akt, caused myotube atrophy reduction in the fusion index
and the mean number of nuclei per myotube. Co-treatment of dif-
ferentiated myotubes with PGRN and 20 lM LY294002 blocked the
PGRN-induced myotubes completely. These results suggest that
the PI(3)K/Akt pathway is essential for PGRN-induced myotube
hypertrophy (Fig. 4A, B and C). The blockage of the mTOR kinase,
a downstream effector of the PI(3)K/Akt pathway, with 100 nM
rapamycin also blunted PGRN-induced hypertrophy (Fig. 4). These
results suggest that the PI(3)K/Akt/mTOR pathway participates in
PGRN-induced myotube hypertrophy.
To further conﬁrm that PGRN, similarly to IGF-1, induces myo-
tube hypertrophy via the PI(3)K/Akt/mTOR pathway, the activation
of downstream targets, such as Akt, GSK-3a/b and p70S6K, were
analyzed by Western blotting. Results show that the phosphoryla-
tion of AKT, GSK-3a/b, and p70S6K in C2C12 myotubes increased in
Fig. 3. PGRN and IGF-1 promoted muscle hypertrophy. Myotubes were treated with 100 ng/ml IGF-1 or 500 ng/ml mouse PGRN at day 4 for 48 h. (A) Myotubes were detected
by immunostaining with an anti-myosin heavy chain antibody, and nuclei were stained with DAPI. (B) average myotube diameters; (C) fusion index; (D) Average number of
nuclei per myotube was determined to validate the myotube hypertrophy phenotype. Data are expressed as means ± S.E. (n = 3). Star symbol indicates signiﬁcant differences.
⁄ indicates p < 0.05.
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with the effects of PI(3)K/Akt/mTOR inhibitors on myotube hyper-
trophy, treatment of C2C12 myotubes with 20 lM LY294002 or
100 nM rapamycin blocked PGRN-induced activations of GSK-3a/
b and p70S6K (Fig. 4D). These results further demonstrate that
PGRN-mediated myotube hypertrophy occurs via the PI3K/AKT/
mTOR pathway.
3.4. PGRN rescues myotube atrophy induced by blocked IGF-1
signaling
Blockage of IGF-1 signaling leads to increased PGRN expression,
and PGRN and IGF-1 share similar functions and signaling path-
ways in myotube hypertrophy, suggesting that PGRNmight be able
to compensate for IGF-1 functions when IGF-1 signaling is blocked.
To test this hypothesis, myotube atrophy was induced by treating
differentiated C2C12 myotubes with 30 lM PQ401 for 2 days. The
addition of PQ401 resulted in an atrophic phenotype with a
decrease in the fusion index and the mean number of nuclei per
myotube. To determine whether PGRN could rescue this myotube
atrophy, which is induced by IGF-1 signaling blockage, atrophic
myotubes were co-treated with 500 ng/ml PGRN and 30 lM
PQ401 for 2 days. These results show that myotube atrophyinduced by PQ401 was rescued by PGRN (Fig. 5A, B and C). In-
creases in the fusion index and the mean number of nuclei per
myotube were observed after PQ401 and PGRN co-treatment, com-
pared to PQ401 treatment alone (Fig. 5B and C). These results show
that PGRN plays a compensatory role in the maintenance of myo-
tube hypertrophy when IGF-1 signaling is blocked (Fig. 5D).
4. Discussion
Numerous in vivo and in vitro studies have demonstrated that
IGF-1 is a critical signaling factor involved in the regulation of post-
natal muscle growth [10,21,22]. In skeletal muscle, IGF-1 serves
multiple functions, including stimulating the proliferation and dif-
ferentiation of myoblasts and promoting protein synthesis [11].
Although the liver is the principal source of circulating IGF-1, sev-
eral reports have demonstrated the importance of locally produced
IGF-1 in muscle growth. Liver-speciﬁc targeted disruption of the
IGF-1 gene does not inﬂuence postnatal growth [23,24], and mus-
cle-speciﬁc mIGF-1 transgene mice display profound hypertrophy
in trunk and limb musculature [25]. In vitro experiments have also
shown that C2C12 myoblasts differentiation relies strongly on the
elevated expression of endogenous IGF-1 [26]. Several lines of evi-
dence suggest that GH may directly regulate the IGF-1 expression
Fig. 4. PGRN induced muscle hypertrophy via the PI(3)K/Akt/mTOR pathway. (A) Myotubes were treated with 20 lM LY294002(LY) or 100 nM rapamycin (Rapa) with or
without 500 ng/ml mouse PGRN at day 4 for 48 h. Myotubes were detected by immunostaining with an anti-myosin heavy chain antibody; (B) fusion index; (C) Average
number of nuclei per myotube was determined to validate the myotube hypertrophy phenotype. Data are expressed as means ± S.E. (n = 3). Star symbol indicates signiﬁcant
differences. ⁄ indicates p < 0.05; ⁄⁄ indicates p < 0.01. (D) Expressions of phospho-GSK-3a/b (Ser21/9) and phospho-p70S6K (Thr389) were measured by Western blotting in 3
independent experiments. a-tubulin was used as the internal control.
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skeletal muscles [27]. Second, GH treatment increases IGF-1 mRNA
expression in skeletal muscle tissues and in the myoblast cell line
C2C12 [28,29]. These results support the notion that GH promotes
postnatal body growth through the local production of IGF-1 in
muscle tissues.
However, locally produced IGF-1 may not be the only growth
factor responsible for postnatal muscle growth. Studies on MKR
mice, which express a dominant negative IGF-1 receptor speciﬁ-
cally in skeletal muscles, show that additional regulatory mecha-
nisms (i.e., outside IGF-1) must exist. MKR mice have lower
muscle weight compared to wild type mice, but the weight differ-
ence diminishes gradually with aging. Meanwhile, the protein con-
tent of the muscle tissue and the number of nuclei per myoﬁber are
both increased in MKR mice [30,31]. MKR mice clearly adapt to the
IGF-1R-free condition through compensatory hyperplasia. PGRN
was initially discovered as a mitogenic growth factor that could
stimulate DNA synthesis and the growth of R cells, which are
3T3 ﬁbroblasts derived from mouse embryos with a targeted dis-
ruption of the IGF-1R gene. This ﬁnding demonstrates that PGRNcould abrogate the requirement for IGF-1R in mouse embryonic
ﬁbroblasts to progress through the cell cycle via the MAP kinase
pathway [32]. These results are similar to those presented in the
current study, which also showed that PGRN circumvent IGF-1 sig-
naling to stimulate muscle growth, although the revealed pheno-
types are muscle cell hypertrophy, rather than cell proliferation.
The ﬁndings suggesting that PGRN is a growth factor can be used
to mediate an adaptive strategy for sustaining partial muscle
growth via the PI3K/Akt/mTOR pathway in the absence of IGF-1
signaling. Recently, sortilin has been identiﬁed as a PGRN binding
partner to regulate PGRN trafﬁcking [33]; moreover, PGRN acting
as a ligand of TNF receptor has also been found to plays a critical
role in the pathogenesis of inﬂammatory arthritis [34]. Although
the receptor which mediated by PGRN cannot be clariﬁed in the
present study, the receptor of PGRN signaling participating as com-
pensatory mechanism in case of IGF-1 absence is worth investigat-
ing further.
In our previous studies, we showed that hepatic PGRN and IGF-
1 expressions are both up-regulated by GH administration [4]. In
the present study, PGRN expression induced by GH administration
Fig. 5. PGRN rescued PQ401-induced muscle atrophy. (A) Muscle atrophy was induced by adding 30 lM PQ401 to the differentiation medium at the beginning of
differentiation (from day 0 to day 4). At day 4, the atrophic myotubes were treated continuously with 30 lM PQ401 with or without 500 ng/ml PGRN for 48 h. Myotubes were
detected by immunostaining with an anti-myosin heavy chain antibody, and nuclei were stained with DAPI; (B) fusion index; (C) Average number of nuclei per myotube was
determined to validate myotube atrophy and hypertrophy. Data are expressed as means ± S.E. (n = 3). Star symbol indicates signiﬁcant differences. ⁄ indicates p < 0.05; ⁄⁄
indicates p < 0.01. (D) A model diagram showing PGRN compensates for blocked IGF-1 signaling during muscle hypertrophy. The red dotted line indicates the PGRN-induced
muscle hypertrophy pathway during IGF-1 signaling blockage. The question mark is used to indicate that the PGRN receptor remains unclear.
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ﬁle of GH-induced PGRN expression is earlier than that of IGF-1.
We speculated that PGRN is upregulated prior to IGF-1, securing
its preparation to serve as a compensatory mechanism in the event
of IGF-1 failure. After correct IGF-1 expression, PGRN is no longer
required and its expression is therefore suppressed. To further
enhance our understanding the role of PGRN plays in the presence
of IGF-1, we also estimated the C2C12 myotube phenotype in the
simultaneous presence of PGRN and IGF-1. Results showed that if
IGF-1 and PGRN are combined, the phenotype of myotube hyper-
trophy is more evident. However, although pERK 1/2 is alsoactivated by the combined addition of IGF-1 and PGRN, the pheno-
type of myotube hyperplasia is too slight to discern. We speculated
that extra PGRN addition might synergistically contribute to IGF-1-
induced myotube hypertrophy (Supplementary Fig. S3). In PGRN is
constitutively expressed in a number of epithelial cells. The tissue
distribution of PGRN, as analyzed by Northern blotting and RT-PCR,
indicates that PGRN is expressed in skeletal muscle, but to date its
function has not been reported [4,35]. In this study, we demon-
strated the function of PGRN in stimulating C2C12 myotube hyper-
trophy. We also dissected the roles of PGRN in the muscle cells and
its association with IGF-1. The GH/IGF-1 axis is the main pathway
3492 S.-Y. Hu et al. / FEBS Letters 586 (2012) 3485–3492responsible for muscle growth in both endocrine and autocrine/
paracrine modes. Other GH downstream targets are believed to
be involved in the regulation of postnatal muscle growth because
muscle growth is maintained even after the loss of IGF-1. Based
on similar functions and the downstream of PGRN and IGF-1, we
proposed a compensatory model in which PGRN mediates muscle
growth and helps to sustain muscle growth in the absence of
IGF-1. We expected our ﬁndings to provide new insights into the
IGF-1-mediated complicated network in regulating muscle growth.
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